Systemic Therapy for Hereditary Breast Cancers

被引：2

作者：

Harvey-Jones, Elizabeth J. ^{[1
]}

Lord, Christopher J. ^{[2
,3
]}

Tutt, Andrew N. J. ^{[1
,2
,4
]}

机构：

[1] Breast Canc Now Res Unit, Guys Hosp Canc Ctr, London SE19RT, England

[2] Kings Coll London, City London Canc Res UK Ctr, London SE19RT, England

[3] CRUK Gene Funct Lab, Inst Canc Res, London SW36JB, England

[4] Breast Canc Now Toby Robins Breast Canc Res Ctr, Inst Canc Res, London SW36JB, England

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2023年 / 37卷 / 01期

关键词：

Hereditary breast cancer; Chemotherapy; PARPi; Drug resistance; Biomarkers; STANDARD NEOADJUVANT CHEMOTHERAPY; PATHOLOGICAL COMPLETE RESPONSE; RANDOMIZED PHASE-II; CELL-FREE DNA; HOMOLOGOUS RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; ADJUVANT CAPECITABINE; INHIBITOR RESISTANCE; REVERSION MUTATIONS; GERMLINE MUTATIONS;

D O I：

10.1016/j.hoc.2022.08.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment options for patients with hereditary breast cancers have expanded significantly in the past 20 years. These include a new FDA-licensed approach to adjuvant therapy, olaparib, that improves OS in those with gBRCA1/2m. However, resistance to platinum-based chemotherapy and PARPi in this cohort of patients is an issue that requires considerable focus. We have discussed standard approaches to treatment, but have touched on the expanse of pre-clinical and early clinical work being undertaken which will likely shape future treatments in this field of medicine.

引用

页码：203 / 224

页数：22

共 50 条

[41] Stem cell therapy for hereditary breast cancer
Rassi, H.
CYTOLOGY AND GENETICS, 2009, 43 (03) : 216 - 222
[42] Identification and management of hereditary breast-ovarian cancers (2004 update)
Eisinger, F.
Bressac, B.
Castaigne, D.
Cottu, P. -H.
Lansac, J.
Lefranc, J. -P.
Lesur, A.
Nogues, C.
Pierret, J.
Puy-Pernias, S.
Sobol, H.
Tardivon, A.
Tristant, H.
Villet, R.
PATHOLOGIE BIOLOGIE, 2006, 54 (04): : 230 - 250
[43] Hereditary breast and ovarian cancers: genetic testing and its clinical implications
Pradnya, Kowtal
Shilpa, Vyas
Narendra, Joshi
Sarin, Rajiv
JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA, 2007, 57 (04): : 298 - 306
[44] Classification of hereditary and sporadic breast cancers based on clinicopathological data.
van Diest, PJ
van der Groep, P
Boater, A
Menko, FH
Michalides, RJAM
van der Wall, E
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S106 - S106
[45] PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
Mehta, Prashant
Bothra, Sneha J.
ADVANCES IN GENETICS, VOL 108, 2021, 108 : 35 - 80
[46] A hypothesis about tumour development and the clinical features of hereditary breast cancers
Olsson, H
EUROPEAN JOURNAL OF CANCER, 2001, 37 (16) : 2023 - 2029
[47] Non-BRCA hereditary breast cancer linked to new cancers
不详
ONCOLOGY-NEW YORK, 2006, 20 (03): : 308 - +
[48] Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes
Parkes, Amanda
Arun, Banu K.
Litton, Jennifer K.
ONCOLOGIST, 2017, 22 (06): : 655 - 666
[49] Breast Conservative Therapy for Multifocal-Multicentric Breast Cancers
Sonthineni, Chaitra
Verma, A.
Agarwal, Gaurav
WORLD JOURNAL OF SURGERY, 2017, 41 (01) : 345 - 345
[50] Systemic therapy for advanced gastroesophageal cancers: progress and pitfalls
Epistola, Raisa J.
Chao, Joseph
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 5

← 1 2 3 4 5 →